Raynaud Disease malady

Categories: Cardiovascular diseases

Aliases & Classifications for Raynaud Disease

Aliases & Descriptions for Raynaud Disease:

Name: Raynaud Disease 12 42 14 69
Raynaud's Disease 12 41
Raynaud's Syndrome [ambiguous] 12
Secondary Raynaud's Phenomenon 69
Raynaud's Syndrome Nos 12
Raynaud's Syndrome 12
Raynaud Phenomenon 69
Raynauds Syndrome 52



raynaud disease:
Inheritance autosomal dominant inheritance


External Ids:

Disease Ontology 12 DOID:10300
ICD10 33 I73.0
MeSH 42 D011928
UMLS 69 C0034734

Summaries for Raynaud Disease

MedlinePlus : 41 raynaud's disease is a rare disorder of the blood vessels, usually in the fingers and toes. it causes the blood vessels to narrow when you are cold or feeling stressed. when this happens, blood can't get to the surface of the skin and the affected areas turn white and blue. when the blood flow returns, the skin turns red and throbs or tingles. in severe cases, loss of blood flow can cause sores or tissue death. primary raynaud's happens on its own. the cause is not known. there is also secondary raynaud's, which is caused by injuries, other diseases, or certain medicines. people in colder climates are more likely to develop raynaud's. it is also more common in women, people with a family history, and those over age 30. treatment for raynaud's may include drugs to keep the blood vessels open. there are also simple things you can do yourself, such as soaking hands in warm water at the first sign of an attack keeping your hands and feet warm in cold weather avoiding triggers, such as certain medicines and stress nih: national heart, lung, and blood institute

MalaCards based summary : Raynaud Disease, also known as raynaud's disease, is related to reynolds syndrome and prostatitis, and has symptoms including abnormality of the skeletal system, abdominal pain and angina pectoris. An important gene associated with Raynaud Disease is CENPB (Centromere Protein B), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Fluid shear stress and atherosclerosis. The drugs Cilostazol and Platelet Aggregation Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and skin, and related phenotypes are cardiovascular system and mortality/aging

Wikipedia : 71 Raynaud syndrome, also known as Raynaud\'s phenomenon, is a medical condition in which spasm of arteries... more...

Related Diseases for Raynaud Disease

Diseases related to Raynaud Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 49)
id Related Disease Score Top Affiliating Genes
1 reynolds syndrome 11.0
2 prostatitis 10.2 APOH IL1R1
3 hypertrichosis 10.2 APOH VWF
4 traumatic glaucoma 10.2 EDN1 PDE5A
5 urogenital adysplasia 10.1 THBD VWF
6 bladder hepatoid adenocarcinoma 10.1 APOH THBD
7 czech dysplasia 10.1 APOH THBD
8 immune-mediated encephalomyelitis 10.1 THBD VWF
9 stiff skin syndrome 10.1 APOH RNPC3
10 aphasia 10.1 EDN1 PDE5A
11 pulpitis 10.1 THBD VWF
12 ophthalmia neonatorum 10.1 APOH THBD
13 septic myocarditis 10.0 THBD VWF
14 agraphia 10.0 CENPB EDN1 RNPC3
15 obstructive jaundice 10.0 APOH EDN1 THBD
16 poikiloderma with neutropenia 10.0 ADRA2C EDN1
17 eastern equine encephalitis 10.0 AGTR1 EDN1
18 aplasia cutis congenita recessive 10.0 AGTR1 EDN1
19 enamel hypoplasia cataract hydrocephaly 10.0 EDN1 THBD VWF
20 neonatal diabetes mellitus 10.0 EDN1 THBD VWF
21 myositis fibrosa 10.0 AGTR1 EDN1
22 zellweger syndrome 10.0 EDN1 VWF
23 petrositis 10.0 AGTR1 EDN1
24 thyroid cancer, anaplastic 10.0 APOH THBD VWF
25 clivus meningioma 10.0 APOH CENPB RNPC3
26 pregnancy loss, recurrent 1 10.0 APOH THBD VWF
27 immunodeficiency, common variable, 6 10.0 APOH THBD VWF
28 cetp-related hyperalphalipoproteinemia 10.0 AGTR1 VWF
29 lymphadenitis 10.0 AGTR1 EDN1
30 haemonchiasis 10.0 APOH THBD VWF
31 bone development disease 10.0 APOH THBD VWF
32 giant papillary conjunctivitis 10.0 APOH THBD VWF
33 eating disorder 10.0 APOH THBD VWF
34 ischemic optic neuropathy 9.9 APOH VWF
35 alpha-2-plasmin inhibitor deficiency 9.9 AGTR1 EDN1 PDE5A
36 acute posterior multifocal placoid pigment epitheliopathy 9.9 AGTR1 EDN1
37 respiratory system disease 9.9 APOH CENPB IL1R1 RNPC3
38 fiedler's myocarditis 9.9 AGTR1 EDN1 VWF
39 acute proliferative glomerulonephritis 9.9 APOH EDN1 THBD VWF
40 pericarditis 9.9 APOH EDN1 THBD VWF
41 pyrimidine metabolic disorder 9.9 AGTR1 EDN1 VWF
42 sydenham chorea 9.8 EDN1 PDE5A THBD VWF
43 macular degeneration, age-related, 12 9.8 AGTR1 EDN1 VWF
44 herpes simplex 9.8 APOH CENPB EDN1 THBD VWF
45 welander distal myopathy 9.7 AGTR1 APOH EDN1 THBD
46 hypertension, essential 9.7 AGTR1 EDN1 THBD VWF
47 budd-chiari syndrome 9.7 AGTR1 APOH THBD VWF
48 myocardial infarction 9.5 AGTR1 EDN1 PDE5A THBD VWF
49 sialadenitis 8.7 ADRA2C AGTR1 APOH CENPB EDN1 IL1R1

Comorbidity relations with Raynaud Disease via Phenotypic Disease Network (PDN):

Deficiency Anemia Esophagitis
Hypertension, Essential Hypothyroidism
Ischemic Heart Disease Peripheral Vascular Disease
Systemic Lupus Erythematosus Systemic Scleroderma

Graphical network of the top 20 diseases related to Raynaud Disease:

Diseases related to Raynaud Disease

Symptoms & Phenotypes for Raynaud Disease

Human phenotypes related to Raynaud Disease:

id Description HPO Frequency HPO Source Accession
1 abnormality of the skeletal system 32 HP:0000924

UMLS symptoms related to Raynaud Disease:

abdominal pain, angina pectoris, chest pain, cold intolerance, constipation, coughing, diarrhea, dyspepsia, edema, fatigue, fever, halitosis, headache, heartburn, icterus, nausea and vomiting, pain, pelvic pain, pruritus, sciatica, syncope, chronic pain, vertigo/dizziness, gastrointestinal gas, symptoms, joint or joint related complaint

MGI Mouse Phenotypes related to Raynaud Disease:

id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.43 ADRA2C AGTR1 EDN1 IL1R1 THBD VWF
2 mortality/aging MP:0010768 9.23 ADRA2C AGTR1 APOH CENPB EDN1 IL1R1

Drugs & Therapeutics for Raynaud Disease

Drugs for Raynaud Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Cilostazol Approved Phase 4 73963-72-1 2754
2 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
3 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
4 Anti-Asthmatic Agents Phase 4
5 Autonomic Agents Phase 4,Early Phase 1
6 Bronchodilator Agents Phase 4
7 Fibrinolytic Agents Phase 4
8 Neuroprotective Agents Phase 4,Early Phase 1
9 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Early Phase 1
10 Phosphodiesterase 3 Inhibitors Phase 4
11 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Early Phase 1
12 Protective Agents Phase 4,Early Phase 1
13 Respiratory System Agents Phase 4
Nitroglycerin Approved, Investigational Phase 3,Phase 2,Phase 1 55-63-0 4510
Acetylcholine Approved Phase 3,Phase 2 51-84-3 187
Tadalafil Approved, Investigational Phase 3,Phase 2 171596-29-5 110635
Iloprost Approved, Investigational Phase 3,Phase 2 78919-13-8 6443959
Nifedipine Approved Phase 3,Early Phase 1 21829-25-4 4485
Amlodipine Approved Phase 2, Phase 3 88150-42-9 2162
Udenafil Approved, Investigational Phase 2, Phase 3 268203-93-6 6918523
Bevacizumab Approved, Investigational Phase 3 216974-75-3
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 5460373 44475014
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
Bupivacaine Approved, Investigational Phase 2, Phase 3 2180-92-9, 38396-39-3 2474
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
leucovorin Approved, Nutraceutical Phase 3 58-05-9 54575, 6560146 143
29 Fasudil Investigational Phase 3 103745-39-7
30 Anticholesteremic Agents Phase 2, Phase 3
31 Antimetabolites Phase 2, Phase 3
32 Atorvastatin Calcium Phase 2, Phase 3 134523-03-8
33 Calcium, Dietary Phase 2, Phase 3, Early Phase 1
34 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2, Phase 3
35 Hypolipidemic Agents Phase 2, Phase 3
36 Lipid Regulating Agents Phase 2, Phase 3
37 Pharmaceutical Solutions Phase 3,Phase 2,Early Phase 1
38 Antihypertensive Agents Phase 2, Phase 3,Phase 1,Early Phase 1
39 Anesthetics Phase 2, Phase 3
40 abobotulinumtoxinA Phase 3,Phase 2
41 Botulinum Toxins Phase 3,Phase 2
42 Botulinum Toxins, Type A Phase 3,Phase 2
43 Cholinergic Agents Phase 3,Phase 2
44 incobotulinumtoxinA Phase 3,Phase 2
45 insulin Phase 3,Phase 2
46 Insulin, Globin Zinc Phase 3,Phase 2
47 Neuromuscular Agents Phase 3,Phase 2
48 Neurotransmitter Agents Phase 3,Phase 2
49 onabotulinumtoxinA Phase 3,Phase 2
50 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3, Early Phase 1

Interventional clinical trials:

(show top 50) (show all 92)
id Name Status NCT ID Phase
1 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4
2 Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048763 Phase 4
3 Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms Unknown status NCT00934427 Phase 3
4 A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3
5 An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus Unknown status NCT00432354 Phase 2, Phase 3
6 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3
7 Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome Completed NCT01291199 Phase 2, Phase 3
8 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT00626665 Phase 3
9 Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00266669 Phase 3
10 St. John's Wort in the Treatment of Raynaud's Phenomenon Completed NCT00351117 Phase 3
11 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT00004786 Phase 3
12 Lab Study of MQX-503 in Treatment of Raynaud's Completed NCT00253331 Phase 2, Phase 3
13 Raynaud's Treatment Study (RTS) Completed NCT00000530 Phase 3
14 Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00419419 Phase 3
15 "As Required" Oral Sildenafil in Raynaud's Phenomenon Completed NCT02050360 Phase 2, Phase 3
16 Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon Completed NCT01280266 Phase 2, Phase 3
17 A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Completed NCT00498615 Phase 3
18 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3
19 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3
20 A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3
21 Effects of Obex in Overweight and Obese Patients Completed NCT02145442 Phase 2, Phase 3
22 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3
23 Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases Recruiting NCT02162537 Phase 3
24 Exparel as a Nerve Block for Severe Hand Pain Terminated NCT02374320 Phase 2, Phase 3
25 Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon Unknown status NCT02356809 Phase 1, Phase 2
26 Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) Unknown status NCT02290613 Phase 2
27 Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease Completed NCT00528242 Phase 2
28 Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon Completed NCT00480753 Phase 2
29 Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator Completed NCT01926847 Phase 2
30 Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon Completed NCT00251238 Phase 2
31 Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon Completed NCT00378521 Phase 2
32 PF-00489791 For The Treatment Of Raynaud's Completed NCT01090492 Phase 2
33 Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02228850 Phase 2
34 Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon Completed NCT02688270 Phase 2
35 Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction Completed NCT00707187 Phase 2
36 Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02260557 Phase 2
37 Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis Completed NCT00004380 Phase 2
38 Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis Completed NCT01670565 Phase 2
39 Imatinib in Systemic Sclerosis Completed NCT00506831 Phase 1, Phase 2
40 Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine Completed NCT00775463 Phase 2
41 Sildenafil for Treatment of Digital Ulcers in Patients With Systemic Sclerosis Completed NCT00624273 Phase 2
42 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma Recruiting NCT02370784 Phase 2
43 CSL Behring Sclero XIII Recruiting NCT02551042 Phase 2
44 Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Recruiting NCT01086540 Phase 2
45 Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis Recruiting NCT02558543 Phase 2
46 A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis Recruiting NCT02663895 Phase 2
47 Riociguat in Scleroderma Associated Digital Ulcers Recruiting NCT02915835 Phase 2
48 A Two-Part Study of BOTOX® Therapy for Ischemic Digits Active, not recruiting NCT01309802 Phase 2
49 SCLERoderma et Adipose-DErived Stroma Cells Not yet recruiting NCT02866552 Phase 2
50 Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon Terminated NCT01315899 Phase 2

Search NIH Clinical Center for Raynaud Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :

Cochrane evidence based reviews: raynaud disease

Genetic Tests for Raynaud Disease

Anatomical Context for Raynaud Disease

MalaCards organs/tissues related to Raynaud Disease:

Lung, Heart, Skin

Publications for Raynaud Disease

Articles related to Raynaud Disease:

id Title Authors Year
Raynaud disease. ( 24211176 )
Intraoral telangiectasias associated with Raynaud disease: a report of two cases. ( 19907728 )
Improvement in both Raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. ( 18627700 )
Long-term effects of thoracic sympathectomy on microcirculation in the hands of patients with primary Raynaud disease. ( 17532934 )
Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. ( 16432094 )
Diabetes mellitus vs. Raynaud disease: different lung vascular bed disorders. ( 12505097 )
Increased prevalence of migraine and chest pain in patients with primary Raynaud disease. ( 1586109 )
Effect of indoramin on finger circulation in patients with Raynaud disease. ( 2423806 )
Raynaud disease with oral manifestations. ( 1119826 )

Variations for Raynaud Disease

Expression for Raynaud Disease

Search GEO for disease gene expression data for Raynaud Disease.

Pathways for Raynaud Disease

Pathways related to Raynaud Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
Show member pathways
2 11.27 EDN1 IL1R1 THBD
3 10.79 AGTR1 EDN1 THBD

GO Terms for Raynaud Disease

Cellular components related to Raynaud Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Weibel-Palade body GO:0033093 8.62 EDN1 VWF

Biological processes related to Raynaud Disease according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of MAP kinase activity GO:0043406 9.49 EDN1 PDE5A
2 hemostasis GO:0007599 9.48 THBD VWF
3 calcium-mediated signaling GO:0019722 9.46 AGTR1 EDN1
4 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway GO:0051482 9.43 AGTR1 EDN1
5 regulation of sensory perception of pain GO:0051930 9.4 ADRA2C EDN1
6 blood coagulation, intrinsic pathway GO:0007597 9.37 APOH VWF
7 positive regulation of cardiac muscle hypertrophy GO:0010613 9.32 EDN1 PDE5A
8 negative regulation of fibrinolysis GO:0051918 9.26 APOH THBD
9 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.16 APOH EDN1
10 regulation of vasoconstriction GO:0019229 9.13 ADRA2C AGTR1 EDN1
11 negative regulation of blood coagulation GO:0030195 8.8 APOH EDN1 THBD

Sources for Raynaud Disease

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
65 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....